Nonalcoholic fatty liver disease: Intravoxel incoherent motion diffusion-weighted MR imaging-An experimental study in a Rabbit model

Radiology

Volumn 270, Issue 1, 2014, Pages 131-140

  Joo, Ijin ^a   Lee, Jeong Min ^a   Yoon, Jeong Hee ^a   Jang, Ja Jun ^a   Han, Joon Koo ^a   Choi, Byung Ihn ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CHOLESTEROL; TRIACYLGLYCEROL;

ALCOHOLIC FATTY LIVER; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHOLESTEROL DIET; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; FEASIBILITY STUDY; HISTOPATHOLOGY; IMAGE ANALYSIS; INTRAVOXEL INCOHERENT MOTION DIFFUSION WEIGHTED IMAGING; LABORATORY DIAGNOSIS; LIPID DIET; LIVER FIBROSIS; LIVER PARENCHYMA; LIVER PERFUSION; MALE; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RABBIT; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; WEIGHT GAIN;

ANIMALS; DIFFUSION MAGNETIC RESONANCE IMAGING; FATTY LIVER; FEASIBILITY STUDIES; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER FUNCTION TESTS; MALE; PREDICTIVE VALUE OF TESTS; RABBITS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84891062992     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13122506     Document Type: Article

References (44)

1. Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2011;25(2):231-244.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346(16):1221-1231.
3. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44(4):865-873.
4. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7(2): 234-238.
5. Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol 2012;23(4):345-352.
6. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51(5):1820-1832.
7. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141(4):1249-1253.
8. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54(4):1208-1216.
9. Hojo M, Watanabe S. Pharmacological therapy of nonalcoholic steatohepatitis. Hepatol Res 2011;41(3):209-216.
10. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006;26(2): 151-156.
11. Salameh N, Larrat B, Abarca-Quinones J, et al. Early detection of steatohepatitis in fatty rat liver by using MR elastography. Radiology 2009;253(1):90-97.
12. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51(3): 433-445.
13. Tsuda N, Okada M, Murakami T. Potential of gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 2007;42(4): 242-247.
14. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355(22):2297-2307.
15. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011; 305(16):1659-1668.
16. Mouzaki M, Allard JP. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. J Clin Gastroenterol 2012;46(6):457-467.
17. Brunt EM, Kleiner DE, Wilson LA, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the Nonalcoholic Steatohepatitis Clinical Research Network. Hepatology 2009;49(3):809-820.
18. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128(7):1898-1906.
19. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986;161(2):401-407.
20. Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 2011;196(6):1351-1361.
21. Chandarana H, Lee VS, Hecht E, Taouli B, Sigmund EE. Comparison of biexponential and monoexponential model of diffusion weighted imaging in evaluation of renal lesions: preliminary experience. Invest Radiol 2011;46(5):285-291.
22. Takahara T, Kwee TC. Low b-value diffusion-weighted imaging: emerging applications in the body. J Magn Reson Imaging 2012;35(6):1266-1273.
23. Luciani A, Vignaud A, Cavet M, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 2008; 249(3):891-899.
24. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echoplanar MR imaging. Radiology 1999;210(3): 617-623.
25. Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 2010;31(3): 589-600.
26. Guiu B, Petit JM, Capitan V, et al. Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study. Radiology 2012;265(1):96-103.
27. Fu JF, Fang YL, Liang L, Wang CL, Hong F, Dong GP. A rabbit model of pediatric nonalcoholic steatohepatitis: the role of adiponectin. World J Gastroenterol 2009;15(8):912-918.
28. Sigmund EE, Vivier PH, Sui D, et al. Intravoxel incoherent motion and diffusion-tensor imaging in renal tissue under hydration and furosemide flow challenges. Radiology 2012;263(3):758-769.
29. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168(2):497-505.
30. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313-1321.
31. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349(9055):825-832.
32. Iellamo F, Legramante JM, Raimondi G, Castrucci F, Massaro M, Peruzzi G. Evaluation of reproducibility of spontaneous baroreflex sensitivity at rest and during laboratory tests. J Hypertens 1996;14(9): 1099-1104.
33. Shigefuku R, Takahashi H, Kobayashi M, et al. Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis? J Gastroenterol 2012; 47(11):1238-1247.
34. Rijzewijk LJ, van der Meer RW, Lubberink M, et al. Liver fat content in type 2 diabetes: relationship with hepatic perfusion and substrate metabolism. Diabetes 2010;59(11): 2747-2754.
35. Kobayashi M, Suzuki M, Ikeda H, et al. Assessment of hepatic steatosis and hepatic tissue blood flow by xenon computed tomography in nonalcoholic steatohepatitis. Hepatol Res 2009;39(1):31-39.
36. Ijaz S, Yang W, Winslet MC, Seifalian AM. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003;10(6):447-456.
37. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004;40(2):386-393.
38. Seifalian AM, Piasecki C, Agarwal A, Davidson BR. The effect of graded steatosis on flow in the hepatic parenchymal microcirculation. Transplantation 1999;68(6):780-784.
39. Anderson SW, Soto JA, Milch HN, et al. Effect of disease progression on liver apparent diffusion coefficient values in a murine model of NASH at 11.7 Tesla MRI. J Magn Reson Imaging 2011;33(4):882-888.
40. Poyraz AK, Onur MR, Kocakoç E, Ogur E. Diffusion-weighted MRI of fatty liver. J Magn Reson Imaging 2012;35(5):1108-1111.
41. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94(4):1018-1022.
42. Tandra S, Yeh MM, Brunt EM, et al. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol 2011;55(3):654-659.
43. Chow AM, Gao DS, Fan SJ, et al. Liver fibrosis: an intravoxel incoherent motion (IVIM) study. J Magn Reson Imaging 2012; 36(1):159-167.
44. Dixon WT. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging: a modest proposal with tremendous potential. Radiology 1988;168(2):566-567.